Multiprofen-CC™ plus standard treatment
Phase 3Small molecule
Multiprofen-CC™ plus standard treatment is one of 44 small molecule programs targeting Arthritis. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
49 competitors in Arthritis
#DrugCompanyPhaseTrials
1Trexall
Jazz PharmaceuticalsApproved
Enbrel
IImmunex
Approved
Medrol
PfizerApproved
Azulfidine
PfizerApproved
Arava
SanofiApproved
Voltaren
NovartisApproved
Xeljanz
PPrism Pharmaceuticals
Approved
Bayer Aspirin
BayerApproved
Actemra
CCelltrion
Approved
Anjeso
Boehringer IngelheimApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- KKAZM Pharmaceuticals Inc.